scholarly journals Healthcare, Medication Utilization and Outcomes of Patients with COPD by GOLD Classification in England

2021 ◽  
Vol Volume 16 ◽  
pp. 2591-2604
Author(s):  
Leah B Sansbury ◽  
Kieran J Rothnie ◽  
Chanchal Bains ◽  
Chris Compton ◽  
Glenn Anley ◽  
...  
Keyword(s):  
Medication Utilization ◽  
Gold Classification

The Impact of Smoking Cessation on Hospitalization and Psychiatric Medication Utilization among People with Serious Mental Illness

2021 ◽  
pp. 1-8
Author(s):  
Jennifer Kertes ◽  
Orit Stein Reisner ◽  
Leon Grunhaus ◽  
Yehuda Neumark
Keyword(s):  
Mental Illness ◽  
Smoking Cessation ◽  
Serious Mental Illness ◽  
Psychiatric Medication ◽  
Medication Utilization ◽  
The Impact

Abstract 13342: Patient Demographics, Clinical Characteristics, Medication Utilization, Medical Resource Use and Outcomes Associated with Patients with Symptomatic Peripheral Artery Disease

Circulation ◽  
2014 ◽  
Vol 130 (suppl_2) ◽  
Author(s):  
Monica Reed Chase ◽  
Prakash Navaratnam ◽  
Howard Friedman ◽  
Kim Heithoff ◽  
Ross J Simpson
Keyword(s):  
Peripheral Artery Disease ◽  
Clinical Characteristics ◽  
Limb Amputation ◽  
Bleeding Complications ◽  
Medical Resource ◽  
Peripheral Artery ◽  
Vascular Events ◽  
Patient Demographics ◽  
Medication Utilization ◽  
Artery Disease

Background: Symptomatic peripheral artery disease (SPAD) [defined as intermittent claudication (IC) and/or critical limb ischemia requiring peripheral revascularization (PRV)] is associated with significant CV and PAD-related morbidity and mortality. However, the real world impact of SPAD has not been well characterized to date. Methods: An algorithm that selectively identifies SPAD patients using a combination of PAD related ICD-9 diagnostic and DRG codes, PRV CPT-4 procedure codes, and IC medication NDC codes was used to select study eligible patients from the MarketScan Commercial and Encounters database from 01/01/06 to 06/30/10. The earliest date of a record of SPAD was the index date and a period of 1 year pre- and 3 years post-index was the study time frame. Patients with stroke/TIA, with bleeding complications and contraindications to anti-platelet therapy were excluded. Descriptive statistics comparing patient demographics, clinical characteristics, medication utilization, medical resource utilization and outcomes (event risk estimates for MI, any stroke, revascularization (coronary and peripheral), limb amputation, acute ischemic event hospitalizations and costs) were generated. Results: A total of 16,663 patients (58.0% male; mean age (± SD) 67.2 ± 12.9 years) were identified with SPAD. SPAD patients had significant comorbidities with 31.5% CAD, 36.0% diabetes, 31.0% hyperlipidemia and 53.1% hypertension. Twenty percent (20%) of SPAD patients were on clopidogrel in the pre-index. Pre-index use of beta-blocker, ACE, ARB and statin use was 42.1%, 37.1%, 21.1% and 48.5% respectively. SPAD patients experienced CV events such as any stroke (8.9%), NSTEMI (4.1%), STEMI (4.8%) and UA (7.5%) in the post-index. SPAD patients also experienced a limb amputation (11.5%), endovascular PRV (17%), and open PRV (14.6%) in the post-index. Annualized SPAD-related hospitalization rates, inpatient costs and outpatients costs were significantly higher in the post-index (0.1 vs 0.01, $2,073 vs $175, $1,313 vs $936; all p<0.0001). Conclusion: In an insured population, SPAD patients have low utilization of preventive medications, high rates of major vascular events (both CV and PAD related) and high costs.

scholarly journals BODE index versus GOLD classification for explaining anxious and depressive symptoms in patients with COPD – a cross-sectional study

2009 ◽  
Vol 10 (1) ◽  
Author(s):  
Georg-Christian Funk ◽  
Kathrin Kirchheiner ◽  
Otto Chris Burghuber ◽  
Sylvia Hartl
Keyword(s):  
Depressive Symptoms ◽  
Cross Sectional Study ◽  
Sectional Study ◽  
Cross Sectional ◽  
Bode Index ◽  
Gold Classification

scholarly journals Prescription reporting with immediate medication utilization mapping (PRIMUM): development of an alert to improve narcotic prescribing

2016 ◽  
Vol 16 (1) ◽  
Author(s):  
Rachel B. Seymour ◽  
◽  
Daniel Leas ◽  
Meghan K. Wally ◽  
Joseph R. Hsu
Keyword(s):  
Medication Utilization

Age-related prescription medication utilization for the management of sickle cell disease among Texas Medicaid patients

2021 ◽  
Vol 17 (4) ◽  
pp. 301-310
Author(s):  
Nidhi Shukla, MS, MBA ◽  
Jamie C. Barner, PhD, FAACP, FAPhA ◽  
Kenneth A. Lawson, PhD, FAPhA ◽  
Karen L. Rascati, PhD
Keyword(s):  
Sickle Cell Disease ◽  
Sickle Cell ◽  
Age Groups ◽  
Dual Therapy ◽  
Cell Disease ◽  
Opioid Use ◽  
Medication Utilization ◽  
Age Related ◽  
Nonopioid Analgesics ◽  
Chi Square Analysis

Introduction: Sickle cell disease (SCD) is associated with recurrent complications and healthcare burden. Although SCD management guidelines differ based on age groups, little is known regarding actual utilization of preventative (hydroxyurea) and palliative therapies (opioid and nonopioid analgesics) to manage complications. This study assessed whether there were age-related differences in SCD index therapy type and SCD-related medication utilization.Design and patients: Texas Medicaid prescription claims from September 1, 2011 to August 31, 2016 were retrospectively analyzed for SCD patients aged 2-63 years who received one or more SCD-related medications (hydroxyurea, opioid, or nonopioid analgesics).Outcome measures: The primary outcomes were SCD index drug type and medication utilization: hydroxyurea adherence, and days’ supply of opioid, and nonopioid analgesics. Chi-square, analysis of variance, and Kruskal–Wallis tests were used.Results: Index therapy percentages for included patients (N = 2,339) were the following: opioids (45.7 percent), nonopioids (36.6 percent), dual therapy-opioids and nonopioids (11.2 percent), and hydroxyurea (6.5 percent), and they differed by age-groups (χ2 = 243.0, p 0.0001). Hydroxyurea as index therapy was higher among children (2-12:9.1 percent) compared to adults (26-40:3.7 percent; 41-63:2.9 percent). Opioids as index therapy were higher among adults (18-25:48.0 percent; 26-40:54.9 percent; 41-63:65.2 percent) compared to children (2-12:36.6 percent). Mean hydroxyurea adherence was higher (p 0.0001) for younger ages, and opioid days’ supply was higher for older ages.Conclusions: Texas Medicaid SCD patients had low hydroxyurea utilization and adherence across all age groups. Interventions to increase the use of hydroxyurea and newer preventative therapies could result in better management of SCDrelated complications and reduce the frequency of pain crises, which may reduce the need for opioid use.

Abstract 359: Unit-Specific Influences on Conscious Sedation Nursing Practices: Comparing Medication Utilization and Patient Outcomes

2020 ◽  
Vol 13 (Suppl_1) ◽  
Author(s):  
Linda Parone ◽  
Sahil Rawal ◽  
Allison Ellis ◽  
Bryant Peterson ◽  
Lourdes Escalante ◽  
...  
Keyword(s):  
Patient Satisfaction ◽  
General Anesthesia ◽  
Clinical Outcomes ◽  
Median Time ◽  
Conscious Sedation ◽  
Adverse Outcomes ◽  
P Value ◽  
Medication Utilization ◽  
American Society ◽  
Cardiac Catherization

Background: Unit-Specific influences may determine the amount of sedation given to patients and lead to deviations in patient satisfaction and clinical outcomes due to vague guidelines (4). This study aims to compare medication utilization, clinical outcomes and patient satisfaction in order to determine safety and efficacy of nurse administrated conscious sedation. Methods: Data from outpatient procedures in Cardiac Catherization Lab (Cath Lab) and Interventional Radiology (IR) departments were collected including comorbidities, labs, procedural characteristics, clinical outcomes, and post-sedation questionnaires. Results: Mean age was 63 ± 14 years and 124 (54.9%) were males. Cath Lab n=132 and IR n=94. Procedure duration(min) was found to be longer in the Cath Lab 55 (37,81), than in IR 24 (16,45), p-value of <0.001. The American Society of Anesthesiologist (ASA) scores of Cath Lab 26(21%), IR 29(30.9%), p-value (0.1). Total amount of versed (mg) given in the Cath Lab 2 (1,2), significantly less than IR 3 (1,4.5) with a p-value of <0.01. Total amount of fentanyl (mcg) for Cath Lab 50(50,100), and IR 100 (50,100) with a p-value of <0.01. Median time between 1 st and 2 nd dose of versed in Cath Lab 0 (0,1), IR 9 (5, 16). Median time between 2 nd and 3 rd dose of versed for Cath Lab 0 (0,0), IR 6 (0,13.5) with a p-value <0.001. Median time between 1 st and 2 nd dose of fentanyl in Cath Lab 1 (0,14.8), IR 12.5 (6.8, 24) with a p-value <0.001. Median time between 2 nd and 3 rd dose of fentanyl for Cath Lab 0 (0,0), IR 0,(0,15), p-value <0.001. Median second dose of versed in Cath Lab 0 (0,1), IR 1 (1,1). Median second dose of fentanyl in Cath Lab 25 0 (0,25), IR 25 (25,50), p-value <0.001. Post-Sedation Questionnaire completed by 57 patients, Cath Lab n=30, IR n=27. Patients that felt uncomfortable during their procedure in Cath Lab 11(36.7%), compared to IR 1 (3.7%). The choice of sedation that patient would choose if undergoing a similar procedure again if under general anesthesia Cath Lab 6(20%), IR 0(0%), p-value 0.03. Patients stated that they would recommend conscious sedation to others based on their previous experience, Cath Lab 24 (80%), IR 27(100%). Conclusion: Patients receiving conscious sedation while undergoing procedures in both the Cath Lab and IR were found to have no adverse outcomes and were considered safe. The procedural duration of catheterization procedures was significantly longer than IR with no adverse outcomes, but patients in the Cath lab received less sedation medication and were found to be less satisfied with their procedure. Patients from Cath Lab received less initial sedation medication and rarely received an additional dose. Cath Lab patients were more likely to not recommended conscious sedation to others (20%), and 6 (20%) stated they would rather undergo a similar procedure under general anesthesia; 36.7% of Cath Lab patients stated that they were uncomfortable during the procedure.

scholarly journals Predictors of Medication Utilization for Opioid Use Disorder Among Medicaid‐Insured HIV Patients in New York

2020 ◽  
Vol 29 (2) ◽  
pp. 151-154
Author(s):  
Sugy Choi ◽  
Rajeev Yerneni ◽  
Shannon Healy ◽  
Mona Goyal ◽  
Charles J. Neighbors
Keyword(s):  
New York ◽  
Opioid Use Disorder ◽  
Opioid Use ◽  
Hiv Patients ◽  
Medication Utilization
Sign in / Sign up

Export Citation Format

Share Document